Weight that resists consistent nutrition and exercise is often driven by metabolic dysfunction, not insufficient effort. You may be doing everything you have been told to do and still watching the scale stay fixed in place. Insulin resistance, hormonal imbalances, and disrupted blood sugar regulation can limit progress regardless of how structured your approach is.
At The Adapt Lab in Solana Beach, GLP-1 for weight loss is prescribed only after advanced metabolic testing identifies the specific factors influencing your weight. Rather than defaulting to standard dosing protocols, treatment often begins with structured microdosing or low-dose GLP-1 strategies matched to your lab results, clinical response, and long-term goals.
GLP-1 stands for glucagon-like peptide-1, a metabolic hormone produced in the small intestine after eating. It plays a central role in three interconnected systems: insulin secretion from the pancreas, gastric emptying rate (the speed at which food exits the stomach), and appetite signaling to the brain.
These functions determine how your body manages blood sugar, hunger timing, and energy use between meals. In patients with insulin resistance (a condition where cells become less responsive to insulin), GLP-1 signaling weakens over time, reducing the body’s ability to coordinate these processes effectively. GLP-1 medications are designed to restore that signaling at a therapeutic level.
Two medications make up most of the GLP-1 treatment options available today.
Together, this dual mechanism often produces a stronger metabolic response than GLP-1 alone. Tirzepatide is FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.
Dr. Larson favors tirzepatide for most non-diabetic patients due to its dual mechanism and typically lower rate of gastrointestinal side effects. Zepbound is the primary peptide used at The Adapt Lab for this reason, though the right medication always depends on your labs and health history.
Not every patient requires the same dose, timeline, or protocol. At The Adapt Lab, each GLP-1 for weight loss plan is built from lab data first, then adjusted based on how your metabolism responds over time.
We do not prescribe GLP-1 medication on request. Before starting treatment, we complete lab testing that evaluates insulin resistance, thyroid function, and key metabolic markers, including HOMA-IR, which stands for Homeostatic Model Assessment of Insulin Resistance, a marker that measures how efficiently your body responds to insulin. This gives us a clearer picture of how your body regulates glucose beyond weight alone.
Two individuals at the same body weight can have very different metabolic profiles. One may require more intensive intervention, while another may respond well to a lower-intensity approach. Lab results determine which path is appropriate.
Most patients begin with a low-dose GLP-1 protocol rather than standard dosing. In many cases, microdosing GLP-1 therapy supports steadier metabolic adaptation with fewer gastrointestinal side effects during the early phase of treatment.
Dosing is adjusted over time based on clinical response, with some patients remaining on lower doses long term when outcomes stay stable and effective. Once a patient reaches their goals, some transition to a maintenance-level microdosing schedule rather than stopping treatment outright, which helps support the metabolic gains achieved during active treatment.
Who this treatment is designed for:
Signs your metabolism needs support:
If several of these describe you, biology is likely playing a bigger role than habit alone. Before starting treatment, you’ll go through a detailed lab workup and a one-on-one consultation with our clinical team, sometimes alongside our broader medical weight loss program.
We review your health history, current medications, and metabolic markers together, then decide together if GLP-1 therapy makes sense for your specific case, or if a different approach would serve you better.
GLP-1 therapy works in combination with nutrition and movement strategies rather than replacing them. Pairing treatment with nutrition counseling reinforces the body’s own metabolic signaling, creating an environment where behavioral changes are easier to maintain. Most patients experience gradual, steady progress rather than rapid fluctuations that are difficult to sustain.
GLP-1 therapy slows the rate food leaves your stomach, which helps reduce blood sugar spikes after meals and supports a more precise insulin response so your pancreas releases insulin in proportion to what you’ve eaten. Over time, this may reduce risk markers associated with insulin resistance and type 2 diabetes, while also decreasing metabolic strain linked to glucose spikes.
GLP-1 therapy strengthens gut-to-brain communication, sending clearer fullness signals so cravings and constant hunger ease up between meals. Many patients report fewer intrusive food cravings and less frequent snacking. Meals feel more satisfying, supporting more consistent eating patterns over time rather than cycles of restriction and rebound eating.
In the SELECT trial in 2023, semaglutide reduced the risk of major cardiovascular events by 20 percent compared to placebo in adults with overweight or obesity and existing cardiovascular disease. These findings apply specifically to semaglutide in patients with established cardiovascular disease and should not be assumed to apply broadly. Still, for patients managing cardiometabolic risk, this is documented clinical evidence rather than early speculation.
You do not need a complete understanding of your metabolic health before scheduling a consultation. A consultation with The Adapt Lab gives you a clear picture of what’s driving your weight and metabolic symptoms, and shows if this treatment makes sense for your case, without pressure to start treatment on day one.
Your consultation covers your health history, current concerns, and metabolic goals, guided by our Metabolic Magic Method. If a low-dose GLP-1 protocol or a microdosing GLP-1 approach sounds like the right fit, the clinical team will guide you through the specific protocol and next steps. Schedule your consultation today and take a structured, clinical step toward understanding your metabolic function.
Semaglutide produced an average 14.9 percent weight loss over 68 weeks in the STEP 1 trial, compared to 2.4 percent with placebo. Tirzepatide produced 16 to 22.5 percent weight loss over 72 weeks in the SURMOUNT-1 trial, depending on dose. Individual results with GLP-1 for weight loss still depend on starting weight, insulin sensitivity, and how the body responds to therapy.
GLP-1 medications have been studied in multi-year clinical trials, including the SELECT trial in 2023, which confirmed a consistent safety profile alongside cardiovascular benefit. Long-term use still requires ongoing clinical oversight, including periodic lab testing and follow-ups, since response and tolerance can change over time.
The most common side effects include nausea, mild gastrointestinal discomfort, and changes in appetite, particularly during the early stages of treatment. A low-dose protocol with gradual titration, the process of slowly adjusting your dose over time, typically reduces these effects. Most symptoms improve as the body adapts to therapy.
Many patients notice appetite changes within 2 to 4 weeks of starting a low-dose GLP-1 for weight loss protocol. Measurable weight changes typically develop over several months as dosing is adjusted and metabolic response improves. In some cases, improvements in insulin sensitivity on a microdose GLP-1 plan appear before significant changes on the scale.
